DE69121401T2 - Hemmung der abstossung bei allogener und concordanter xenogener transplantation - Google Patents
Hemmung der abstossung bei allogener und concordanter xenogener transplantationInfo
- Publication number
- DE69121401T2 DE69121401T2 DE69121401T DE69121401T DE69121401T2 DE 69121401 T2 DE69121401 T2 DE 69121401T2 DE 69121401 T DE69121401 T DE 69121401T DE 69121401 T DE69121401 T DE 69121401T DE 69121401 T2 DE69121401 T2 DE 69121401T2
- Authority
- DE
- Germany
- Prior art keywords
- cyclosporin
- survival
- immunosuppressant
- transplant
- rejection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002054 transplantation Methods 0.000 title description 15
- 230000005764 inhibitory process Effects 0.000 title description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 52
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 52
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 52
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 52
- 230000004083 survival effect Effects 0.000 claims abstract description 45
- 101710172562 Cobra venom factor Proteins 0.000 claims abstract description 44
- 239000004074 complement inhibitor Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 26
- 229940124073 Complement inhibitor Drugs 0.000 claims abstract description 23
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 18
- 210000002925 A-like Anatomy 0.000 claims abstract description 12
- 239000003018 immunosuppressive agent Substances 0.000 claims description 21
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 20
- 230000001861 immunosuppressant effect Effects 0.000 claims description 20
- 230000000735 allogeneic effect Effects 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000024203 complement activation Effects 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 150000002066 eicosanoids Chemical class 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 241000894007 species Species 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 206010052779 Transplant rejections Diseases 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 8
- 241000699800 Cricetinae Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000002435 venom Substances 0.000 description 7
- 210000001048 venom Anatomy 0.000 description 7
- 231100000611 venom Toxicity 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 102000050019 Membrane Cofactor Human genes 0.000 description 4
- 101710146216 Membrane cofactor protein Proteins 0.000 description 4
- 241000270295 Serpentes Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002642 cobra venom Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000003998 snake venom Substances 0.000 description 4
- 108010009575 CD55 Antigens Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 3
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000272041 Naja Species 0.000 description 2
- 241000272140 Naja kaouthia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000757814 Canis lupus x Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010048748 Graft loss Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710181904 Venom factor Proteins 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 108010019248 cyclosporin C Proteins 0.000 description 1
- 108010019249 cyclosporin G Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909007971A GB9007971D0 (en) | 1990-04-09 | 1990-04-09 | Pharmaceutical formulations |
| PCT/GB1991/000522 WO1991015221A1 (en) | 1990-04-09 | 1991-04-04 | Inhibition of allograft and concordant xenograft rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69121401D1 DE69121401D1 (de) | 1996-09-19 |
| DE69121401T2 true DE69121401T2 (de) | 1996-12-12 |
Family
ID=10674123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69121401T Expired - Fee Related DE69121401T2 (de) | 1990-04-09 | 1991-04-04 | Hemmung der abstossung bei allogener und concordanter xenogener transplantation |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0527762B1 (enExample) |
| JP (1) | JP3518547B2 (enExample) |
| CN (1) | CN1040178C (enExample) |
| AT (1) | ATE141167T1 (enExample) |
| AU (1) | AU7555591A (enExample) |
| CZ (1) | CZ283119B6 (enExample) |
| DE (1) | DE69121401T2 (enExample) |
| DK (1) | DK0527762T3 (enExample) |
| ES (1) | ES2090325T3 (enExample) |
| GB (1) | GB9007971D0 (enExample) |
| GR (1) | GR3021642T3 (enExample) |
| HK (1) | HK48597A (enExample) |
| IE (1) | IE911153A1 (enExample) |
| IL (1) | IL97788A (enExample) |
| IN (1) | IN173149B (enExample) |
| MY (1) | MY106158A (enExample) |
| NZ (1) | NZ237739A (enExample) |
| PT (1) | PT97277B (enExample) |
| SG (1) | SG47465A1 (enExample) |
| SK (1) | SK279949B6 (enExample) |
| WO (1) | WO1991015221A1 (enExample) |
| ZA (1) | ZA912467B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030379A2 (en) * | 1999-10-27 | 2001-05-03 | Alexandra Lucas | Compositions and methods for preventing and treating transplant rejection |
| JP2004509171A (ja) | 2000-09-29 | 2004-03-25 | ゾーン、 ロバート ズィー． | 炎症及び免疫反応の治療方法及びその組成物 |
| NZ551308A (en) * | 2004-05-14 | 2009-06-26 | Alexion Pharma Inc | Prolongation of survival of an allograft by inhibiting complement activity |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| SI3028716T1 (sl) | 2006-10-10 | 2021-01-29 | Regenesance B.V. | Komplementarna inhibicija za izboljšano regeneracijo živcev |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
-
1990
- 1990-04-09 GB GB909007971A patent/GB9007971D0/en active Pending
-
1991
- 1991-04-02 MY MYPI91000550A patent/MY106158A/en unknown
- 1991-04-03 ZA ZA912467A patent/ZA912467B/xx unknown
- 1991-04-03 IN IN265MA1991 patent/IN173149B/en unknown
- 1991-04-04 EP EP91907303A patent/EP0527762B1/en not_active Expired - Lifetime
- 1991-04-04 WO PCT/GB1991/000522 patent/WO1991015221A1/en not_active Ceased
- 1991-04-04 DE DE69121401T patent/DE69121401T2/de not_active Expired - Fee Related
- 1991-04-04 JP JP50651691A patent/JP3518547B2/ja not_active Expired - Fee Related
- 1991-04-04 ES ES91907303T patent/ES2090325T3/es not_active Expired - Lifetime
- 1991-04-04 AU AU75555/91A patent/AU7555591A/en not_active Abandoned
- 1991-04-04 SG SG1996001900A patent/SG47465A1/en unknown
- 1991-04-04 DK DK91907303.1T patent/DK0527762T3/da active
- 1991-04-04 AT AT91907303T patent/ATE141167T1/de not_active IP Right Cessation
- 1991-04-08 IE IE115391A patent/IE911153A1/en not_active IP Right Cessation
- 1991-04-08 NZ NZ237739A patent/NZ237739A/xx unknown
- 1991-04-08 PT PT97277A patent/PT97277B/pt not_active IP Right Cessation
- 1991-04-08 IL IL97788A patent/IL97788A/en not_active IP Right Cessation
- 1991-04-09 SK SK988-91A patent/SK279949B6/sk unknown
- 1991-04-09 CZ CS91988A patent/CZ283119B6/cs not_active IP Right Cessation
- 1991-04-09 CN CN91102859A patent/CN1040178C/zh not_active Expired - Fee Related
-
1996
- 1996-11-14 GR GR960403013T patent/GR3021642T3/el unknown
-
1997
- 1997-04-17 HK HK48597A patent/HK48597A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2090325T3 (es) | 1996-10-16 |
| SK279949B6 (sk) | 1999-06-11 |
| CZ283119B6 (cs) | 1998-01-14 |
| ATE141167T1 (de) | 1996-08-15 |
| JP3518547B2 (ja) | 2004-04-12 |
| JPH05507266A (ja) | 1993-10-21 |
| DK0527762T3 (da) | 1996-09-02 |
| GR3021642T3 (en) | 1997-02-28 |
| DE69121401D1 (de) | 1996-09-19 |
| IL97788A0 (en) | 1992-06-21 |
| EP0527762A1 (en) | 1993-02-24 |
| MY106158A (en) | 1995-03-31 |
| PT97277B (pt) | 1998-08-31 |
| SG47465A1 (en) | 1998-04-17 |
| AU7555591A (en) | 1991-10-30 |
| IE911153A1 (en) | 1991-10-09 |
| CN1056240A (zh) | 1991-11-20 |
| IL97788A (en) | 1998-02-08 |
| ZA912467B (en) | 1992-12-30 |
| IN173149B (enExample) | 1994-02-19 |
| NZ237739A (en) | 1993-09-27 |
| PT97277A (pt) | 1992-01-31 |
| GB9007971D0 (en) | 1990-06-06 |
| EP0527762B1 (en) | 1996-08-14 |
| HK48597A (en) | 1997-04-25 |
| CN1040178C (zh) | 1998-10-14 |
| CS9100988A2 (en) | 1991-12-17 |
| WO1991015221A1 (en) | 1991-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3689909T2 (de) | Verwendung eines GHL-Cu enthaltenden Stoffes zur Herstellung eines Arzneimittels für Wunden. | |
| DE69326351T2 (de) | Verwendung von enzymen insbesondere brorelain zur behandlung von nicht-infektiöser diarrhöe | |
| DE69008258T2 (de) | S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates. | |
| Swingle | Experiments on the metamorphosis of neotenous amphibians | |
| Kocan | The use of ivermectin in the treatment and prevention of infection with Parelaphostrongylus tenuis (Dougherty)(Nematoda: Metastrongyloidea) in white-tailed deer (Odocoileus virginianus Zimmermann) | |
| EP0527762B1 (en) | Inhibition of allograft and concordant xenograft rejection | |
| DE69124380T2 (de) | Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten | |
| Armson et al. | Murine strongyloidiasis: the effects of cyclosporin A and thiabendazole administered singly and in combination | |
| Rogers et al. | Eosinophile in human skin homografting. | |
| DE60006519T2 (de) | Glutathion-reduktase zur behandlung und prophylaxe von aids | |
| DE3220326C2 (de) | Carcinom-Therapeutikum | |
| US20010018051A1 (en) | Inhibition of allograft and concordant xenograft rejection | |
| EP1240904B1 (de) | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstossung von Xenotransplantaten in Säugetieren | |
| DE69332904T2 (de) | Hemmung von hiv-infektion | |
| DE69532557T2 (de) | Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene | |
| EP0271023A2 (de) | Verwendung von Dihydrophenylaminosäurederivaten und diese enthaltende Arzneimittel zur Immunmodulation und Cytostase | |
| US4430329A (en) | Synergistic treatment of adult canine heartworm with thiacetarsamide and ivermectin | |
| EP0256385A2 (de) | Verwendung von 15-Deoxyspergualin als Arzneimittel | |
| DE3910568C2 (enExample) | ||
| DE2610426A1 (de) | Therapeutisches mittel zur behandlung der haemorrhagischen pneumonie von nerzen und der rindermastitis, hervorgerufen durch pseudomonas aeruginosa | |
| DE69434256T2 (de) | Immunglobulin-Infusion bei der Xenotransplantation | |
| WO1990006768A1 (de) | Verwendung von transferrin zur bekämpfung der toxischen wirkung des endotoxins bei der endotoxinämie | |
| Black et al. | Cyclosporine-induced long-term allograft survival and its potential in posttrauma tissue replacement | |
| North et al. | Antagonism between the actions of staphylococcal toxin and tiger snake venom | |
| EP0183253A2 (de) | Arzneimittel enthaltend einen aus den Peyer'schen Plaques hergestellten Organextrakt zur Behandlung bei Diabetes Mellitus und Pankreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |